Trial Profile

Positron emission tomography Repeatability Evaluation of Tissue Zirconium 89ZR CrEfmirLimab berdoxam uptake (PRETZCEL)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Crefmirlimab (Primary)
Indications Malignant melanoma; Renal cell carcinoma
Focus Registrational; Therapeutic Use
Acronyms PRETZCEL
Sponsors ImaginAb Inc

Most Recent Events

03 Dec 2024 Status changed to discontinued.
03 Oct 2023 Planned End Date changed from 31 Oct 2024 to 31 Dec 2024.
12 Dec 2022 According to ISRCTN: Current Controlled Trials record, recruitment is expected to begin on 15 Dec 2022 and recruitment completion is expected on 31 Oct 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com